Hematologic and Cytogenetic Responses to Imatinib Mesylate in Chronic Myelogenous Leukemia | Zendy

Hagop Kantarjian | Zendy; Charles L. Sawyers | Zendy; Andreas Hochhaus | Zendy; François Guilhot | Zendy; Charles A. Schiffer | Zendy; Carlo GambacortiPasserini | Zendy; Dietger Niederwieser | Zendy; Debra Resta | Zendy; Renaud Capdeville | Zendy; Ulrike Zoellner | Zendy; Moshe Talpaz | Zendy; Brian J. Druker | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Hematologic and Cytogenetic Responses to Imatinib Mesylate in Chronic Myelogenous Leukemia

Author(s) -

Hagop Kantarjian,

Charles L. Sawyers,

Andreas Hochhaus,

François Guilhot,

Charles A. Schiffer,

Carlo GambacortiPasserini,

Dietger Niederwieser,

Debra Resta,

Renaud Capdeville,

Ulrike Zoellner,

Moshe Talpaz,

Brian J. Druker

Publication year - 2002

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa011573

Subject(s) - medicine , imatinib mesylate , chronic myelogenous leukemia , imatinib , philadelphia chromosome , tyrosine kinase inhibitor , gastroenterology , leukemia , adverse effect , interferon alfa , alpha interferon , immunology , interferon , chromosomal translocation , cancer , myeloid leukemia , biology , biochemistry , gene

Chronic myelogenous leukemia (CML) is caused by the BCR-ABL tyrosine kinase, the product of the Philadelphia chromosome. Imatinib mesylate, formerly STI571, is a selective inhibitor of this kinase.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research